Rezafungin
[CAS# 1396640-59-7]

Identification

• Classification: API >> Synthetic anti-infective drugs >> Antifungal drugs
• Name: Rezafungin
• Synonyms: 2-[[6-[1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,25-trihydroxy-3,15-bis(1-hydroxyethyl)-26-methyl-2,5,8,14,17,23-hexaoxo-18-[[4-[4-(4-pentoxyphenyl)phenyl]benzoyl]amino]-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-21-yl]oxy]ethyl-trimethylazanium
• Molecular Formula: C₆₃H₈₅N₈O₁₇⁺
• Molecular Weight: 1226.39
• CAS Registry Number: 1396640-59-7
• SMILES: CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC(=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC=C(C=C7)O)O)O)C(C)O)C)O)OCC[N+](C)(C)C)O

Discovory and Applicatios

Rezafungin, a novel echinocandin antifungal agent, was discovered through innovative drug design efforts aimed at developing improved therapies for invasive fungal infections. It was synthesized and characterized by researchers at Cidara Therapeutics, Inc., utilizing a rational drug design approach based on the structure-activity relationship of echinocandin compounds. Rezafungin was designed to possess enhanced pharmacokinetic properties, including a long half-life and once-weekly dosing regimen, compared to existing echinocandins.

Rezafungin is indicated for the treatment of invasive fungal infections caused by Candida species and Aspergillus species. These infections, including candidemia, invasive candidiasis, and invasive aspergillosis, pose significant risks to immunocompromised patients, such as those undergoing chemotherapy or organ transplantation. Rezafungin's broad spectrum of activity and favorable pharmacokinetic profile make it a valuable addition to the armamentarium of antifungal agents for the management of these life-threatening infections. Rezafungin may also be used prophylactically in high-risk patients to prevent invasive fungal infections. This includes individuals undergoing hematopoietic stem cell transplantation, solid organ transplantation, or those with prolonged neutropenia. Prophylactic administration of rezafungin helps reduce the incidence of fungal infections and improve patient outcomes in vulnerable populations. Rezafungin's extended half-life and once-weekly dosing regimen offer advantages in antifungal stewardship programs, promoting adherence to therapy and reducing the burden of frequent dosing on patients and healthcare providers. As a novel echinocandin, rezafungin may offer benefits in managing antifungal resistance, particularly in Candida species with reduced susceptibility to existing echinocandins.